Michael Cattaneo

Vice President Medical Affairs at Cingulate Therapeutics - Roeland Park, KS, US

Michael Cattaneo's Colleagues at Cingulate Therapeutics
Jeff Bennett

Deputy General Counsel

Contact Jeff Bennett

Kari Fogleman

Executive Assistant & Office Manager

Contact Kari Fogleman

Stephen Abele

Senior Director Manufacturing and Development

Contact Stephen Abele

Lou Horn

Chief Financial Officer

Contact Lou Horn

View All Michael Cattaneo's Colleagues
Michael Cattaneo's Contact Details
HQ
913-942-2300
Location
Kansas City Metropolitan Area
Company
Cingulate Therapeutics
Michael Cattaneo's Company Details
Cingulate Therapeutics logo, Cingulate Therapeutics contact details

Cingulate Therapeutics

Roeland Park, KS, US • 20 - 49 Employees
Major Drugs

Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), we believe there are multiple therapeutic areas where our PTR technology may be employed to develop additional product candidates, notably anxiety disorders.

N/A
Details about Cingulate Therapeutics
Frequently Asked Questions about Michael Cattaneo
Michael Cattaneo currently works for Cingulate Therapeutics.
Michael Cattaneo's role at Cingulate Therapeutics is Vice President Medical Affairs.
Michael Cattaneo's email address is ***@cingulatetherapeutics.com. To view Michael Cattaneo's full email address, please signup to ConnectPlex.
Michael Cattaneo works in the Major Drugs industry.
Michael Cattaneo's colleagues at Cingulate Therapeutics are Jeff Bennett, Spencer Chestnut, Kari Fogleman, Stephen Abele, Matthew Brams, Lou Horn, Lou Horn and others.
Michael Cattaneo's phone number is 913-942-2300
See more information about Michael Cattaneo